CONVATEC ACQUISITION OF MERCK'S CALGON VESTAL LABS
This article was originally published in The Gray Sheet
Executive Summary
CONVATEC ACQUISITION OF MERCK'S CALGON VESTAL LABS would create a wound management/skin care company with a sales force of more than 1,000. Under a definitive agreement announced Nov. 3, Bristol-Myers Squibb's ConvaTec subsidiary would acquire Merck's Calgon for $261.5 mil. in a cash transaction.